Pharmaceuticals
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
PLANEGG/MUNICH, Germany and SHANGHAI, China, Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug applic...
2020-09-18 04:05
11031
First patient in treatment in RhoVac's clinical phase IIb study in Sweden
STOCKHOLM, Sept. 17, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, onSeptember 17 2020, that the first patient in Sweden is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac"). The first patient in Sweden is enrolled in the cli...
2020-09-17 23:51
3424
Dr. Steven Yu Joins ChemPartner as Vice President of Regulated Bioanalysis
SHANGHAI, Sept. 17, 2020 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment ofSteven Yu, Ph.D. as Vice President of Regulated Bioanalysis at the company headquarters inShanghai, China. Dr. Yu has more than 15 years of experience in drug development and extensive expertise in...
2020-09-17 23:01
2460
Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.
NANJING, China, Sept. 17, 2020 /PRNewswire/ -- On September 16th, 2020, GenScript ProBio and REMD Biotherapeutics Inc. (REMD) announced that REMD has licensed a bispecific antibody derived from the Single-domain antibody fused to Monoclonal Ab (SMAB) platform developed by GenScript ProBio. REMD i...
2020-09-17 22:00
2229
Viva Biotech's Portfolio Company Dogma Therapeutics Reached the Acquisition Agreement with AstraZeneca on Dogma's Oral PCSK9 Inhibitor Program
CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Dogma Therapeutics ("Dogma"), a Viva Biotech Portfolio Company, has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma will receive upfront as well as downstream payments linked to global regulatory and commerc...
2020-09-17 20:25
4579
Samsung Biologics signs development agreement with Panolos for solid tumor treatment
INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung Biologics will provide a full scope of its developm...
2020-09-17 08:43
2624
Alter Pharma Group Adopts Movilitas.Cloud to Ensure Safer Goods and EU FMD Compliance Throughout the Product Path and Changes in Packaging
Solution supports requirements for traceability down to the single package level and optimizes the repackaging process for increased efficiency and safer medicine COLUMBIA, Maryland, Sept. 16, 2020 /PRNewswire/ -- Movilitas announced that the Alter Pharma Group, a pharmaceutical group active in ...
2020-09-16 21:39
2446
Sanofi partners with Health2Sync to deliver an innovative digital solution to patients and healthcare providers, paving the way for digital therapeutics in diabetes
* Starting in Taiwan, this partnership aims to on-board clinics and hospitals nationwide over the next 3 years * Health2Sync to provide patient management software, patient app, and analytics to facilitate smart insulin management * Bi-lateral digital touchpoints empower patients with person...
2020-09-16 19:12
2140
Transcenta Successfully Scaled up the Continuous Perfusion Process and Completed GMP Manufacturing of a Novel Bispecific Antibody for Cancer Immunotherapy
SUZHOU, China and HANGZHOU, China, Sept. 15, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company, today announced success in scaling up the continuous perfusion process to 200L and completion of GMP production of a bispecific antibody for a Phase 1 clinical study. "This is an impo...
2020-09-15 23:00
1705
CIRT-EU Registry for SIR-Spheres(R) Therapy presented at CIRSE 2020 Summit
Largest European-wide observational, multicenter registry of SIR-Spheres Y-90 resin microspheres for liver tumors conducted by CIRSE reports safety and survival data WOBURN, Mass., Sept. 15, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies...
2020-09-15 20:00
2268
Sihuan Pharmaceutical (0460.HK): Under innovation transformation, an internationalized new pattern in construction
HONG KONG, Sept. 15, 2020 /PRNewswire/ -- Recently, share price of Sihuan Pharmaceutical (0460.HK) continued to rise, hittingHK$1.09 per share, up 53.52% from its low onMay 25. Judging from the stock price trend, the stock price of Sihuan Pharmaceutical seems to have entered the stage of reboundi...
2020-09-15 18:05
9396
Elekta introduces new radiotherapy solution to help address worldwide cancer burden
- Elekta Harmony to shorten treatment times and reduce footprint while maintaining high precision STOCKHOLM, Sept. 15, 2020 /PRNewswire/ -- Elekta (EKTA-B.ST) today introduced its Elekta Harmony* linear accelerator (linac), a cancer treatment system designed to meet healthcare centers' need for ...
2020-09-15 18:03
10500
MAGHREB PHARMA Expo to contribute to Algeria plans to export for US$ 5 billion locally produced drugs by 2025
ALGIERS, Algeria, Sept. 15, 2020 /PRNewswire/ --Easyfairs Northeral, the organizer of MAGHREB PHARMA Expo has announced new dates for its annual international tradeshow for the pharmaceutical industry inNorth Africa. In this context, the Algerian Pharmaceutical Industry Minister,Lotfi Benbahmed, ...
2020-09-15 14:00
3182
Standigm Partners with Excelra for GOSTAR to Enhance its AI-driven Drug Discovery Process
HYDERABAD, India and SEOUL, South Korea, Sept. 15, 2020 /PRNewswire/ -- Excelra
2020-09-15 10:00
3636
Concept Medical announces index patient enrolment in world's first Randomized Controlled Trial with Sirolimus Coated Balloon for the treatment of Superficial Femoral Artery (SFA) in Peripheral Artery Disease
SINGAPORE, Sept. 15, 2020 /PRNewswire/ -- Concept Medical Inc.,
2020-09-15 03:41
3690
TIKOMED'S ILB(R) restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants
VIKEN, Sweden, Sept. 14, 2020 /PRNewswire/ -- A new study on TIKOMED's lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today. The data from the rodent model studying severe traumatic brain injury ...
2020-09-14 20:35
1897
Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer
SUZHOU, China and ROCKVILLE, Md., Sept. 14, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug ...
2020-09-14 18:35
2172
Countering counterfeit medicines in the fast-paced world of e-commerce
BANGKOK, Sept. 14, 2020 /PRNewswire/ -- Research shows that counterfeit medicine cannot cure illnesses and can cause moreharm to your health. Counterfeit medicines have been in the market for a long time, and without sufficient awareness, consumption of these substances can lead to unexpected sy...
2020-09-14 16:59
3672
Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020
* New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer * Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib† from largest ongoing st...
2020-09-14 10:41
2660
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist
SHANGHAI, Sept. 14, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that it has filed investigational new drug application (IND) with US FDA for its non-alcoholic steatohepatitis (NASH) drug candidate ASC42. ASC42 is an in-...
2020-09-14 08:30
3760
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6801
